R&D
Leveraging on in-house R&D platform,the Company maintains a pipeline of projects in various clinical stages,covering a wide range of fields of indication
Remain True to Our Original Aspiration –Innovation Driven
In 1996, we established production plants for API (rb-bFGF) and formulations
In 1998, the first rb-bFGF surgical product Beifuji launched in China
In 1999, the first rb-bFGF ophthalmic product Beifushu Eye Drops launched in China
IN-HOUSE R&D PLATFORMS
Solid R&D of biologic APIs and drug products
Growth
Factor
rb-bFGF/rh-bFGF and others for the treatment of ocular surface wounds, topical wounds, nerve injuries
Antibody
mAb, bsAb, sdAb, scFv, ADC/FDC, etc.
Drug Formulation
Successfully developed eyedrops, eye gel, spray, lyophilized powder, gel
Blow-Fill-Seal
(BFS)
Producing preservative-free single-dose drugs in particular ocular drugs
 
R&D CAPABILITIES
INNOVATION
BASE
· Provincial Enterprise Technology Centre
· Guangdong Provincial Cytokine Engineering Technology Research Centre
· Guangdong Provincial Ophthalmic Medicine Engineering Technology Research Centre
· Guangdong Province Aerosol Inhalation Formulation Engineering Technology Research Centre
· The teaching and practice base of South China University of Technology, Wenzhou Medical University and Zunyi Medical University
· National Postdoctoral Research Station
HONOURS & AWARDS
· Undertook National "Ninth Five-Year Plan" major scientific and technological research project
· Undertook National "Torch Plan" Project
· Undertook National "Major New Drug Creation" Project
· Owns 30 patents, including 23 invention patents, 3 utility patents, 4 design patent
· rb-bFGF eye drops was awarded one of the National Outstanding Innovation
· rb-bFGF gel was awarded one of the National Outstanding Innovation
· Honoured with the second prize of "National Scientific and Technology Progress Award" issued by the State Council in 2004 and 2018
R&D STRATEGY
To the Future — Broad Innovation Prospects
Continued product development,Improve drug discovery

Ophthalmology: fast-follower and to identify new generation of therapeutics
Oncology: to be global stakeholder
Research Centre (Zhuhai, PRC)
· Conduct translational research
· Undertake for NMPA registration of in-house and overseas projects
· Talent incubation: National Post-Doctoral Research Centre set up in Zhuhai
Research Centre (U.S.)
· Started in Mar 2020
· Led by Dr. XUE Qi, Chief Scientific Officer of Company
· Responsible for drug discovery and early stage product development in novel therapeutics
This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.